Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Gains from Investment Securities: 2017-2024

Historic Gains from Investment Securities for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $7.5 million.

  • BridgeBio Pharma's Gains from Investment Securities fell 7.69% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 5.50%. This contributed to the annual value of $7.5 million for FY2024, which is 9.39% up from last year.
  • BridgeBio Pharma's Gains from Investment Securities amounted to $7.5 million in FY2024, which was up 9.39% from $6.9 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Gains from Investment Securities ranged from a high of $7.5 million in FY2024 and a low of -$7.1 million during FY2021.
  • Its 3-year average for Gains from Investment Securities is $4.1 million, with a median of $6.9 million in 2023.
  • Per our database at Business Quant, BridgeBio Pharma's Gains from Investment Securities crashed by 204.91% in 2021 and then surged by 416.32% in 2023.
  • BridgeBio Pharma's Gains from Investment Securities (Yearly) stood at $6.8 million in 2020, then plummeted by 204.91% to -$7.1 million in 2021, then soared by 69.33% to -$2.2 million in 2022, then soared by 416.32% to $6.9 million in 2023, then climbed by 9.39% to $7.5 million in 2024.